
    
      This is a multicenter, prospective, translational study. Pharmacological treatments will not
      be object of the present study. Patients will follow the prescribed therapeutic indications
      according to regular clinical practice. Biological samples and clinical data will be
      collected at fixed timepoints.

      Aim of the study is to evaluate the immunogenic profile of AML cases according to immune
      checkpoint molecule expression.

      A total of 75 AML patients affected by primary or secondary AML, at diagnosis ( 45 patients)
      or relapse (30 patients) will be enrolled in the protocol (18 months for patient enrolment).
      Blood,BM and saliva samples will be collected from each patients; for patients enrolled at
      diagnosis, samples will be collected before and after treatment with hypomethylating agents.
    
  